Share Price | Intensity Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Intensity Therapeutics, Inc.?

Market Cap: As of Jun 18, Intensity Therapeutics, Inc. has a market capitalization of 4.32 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 0.00 million and a net profit of -15.01 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 2.92 million, while total assets were reported at 4.78 million.

Q: What does Intensity Therapeutics, Inc. do?

Overview: Intensity Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot: Net Profit: -3 Million (Quarterly Results - Mar 2025) Market Cap: USD 4.32 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.90 Return on Equity: -1,501.20% Price to Book: 4.32Contact Details: Registrar Address: Not available.

Q: Is Intensity Therapeutics, Inc. technically bullish or bearish?

As of 12 August 2025, the technical trend for Intensity Therapeutics, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The Bollinger Bands and moving averages are bearish on the daily and monthly time frames, and the KST shows a mildly bullish signal on the weekly but bearish on the monthly. The Dow Theory reflects a mildly bearish trend on the weekly and no trend on the monthly.In terms of performance, the stock has seen a significant decline year-to-date with a return of -86.36%, compared to the S&P 500's gain of 12.22%. Over the past year, the stock has dropped -94.24%, while the S&P 500 has risen by 17.14%. Overall, the current technical stance is mildly bearish, with key indicators suggesting a lack of strong upward momentum.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

847.91 k

Shareholding (Sep 2025)

FII

0.05%

Held by 2 FIIs

DII

98.78%

Held by 1 DIIs

Promoter

0.00%

How big is Intensity Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Intensity Therapeutics, Inc. has a market capitalization of 4.32 million, with net sales of 0.00 million and a net profit of -15.01 million over the last four quarters. The company's shareholder's funds are 2.92 million, and total assets are 4.78 million.

View full answer

What does Intensity Therapeutics, Inc. do?

22-Jun-2025

Intensity Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $3 million and a market cap of $4.32 million. Key financial metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -1,501.20%.

View full answer

Is Intensity Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 12, 2025, Intensity Therapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, including a significant year-to-date decline of -86.36% compared to the S&P 500's gain of 12.22%.

View full answer

Compare Intensity Therapeutics, Inc. with Similar Stocks

Spero Therapeutics, Inc.Shattuck Labs, Inc.Nkarta, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 24 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.97

Return on Equity

-162.50%

Price to Book

3.30

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-36.67%

6 Months

27.56%

1 Year

-85.01%

2 Years

-92.85%

3 Years

0.0%

4 Years

0.0%

5 Years

-99.18%

Intensity Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

1.85%

EBIT to Interest (avg)

-8.19

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.90

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

6.62%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.99

EV to EBIT

-0.40

EV to EBITDA

-0.40

EV to Capital Employed

-6.09

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-1501.20%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (1.17%)

Foreign Institutions

Held by 2 Foreign Institutions (0.05%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 22.86% vs -52.17% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.70",
          "val2": "-3.60",
          "chgp": "25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.70",
          "val2": "-3.50",
          "chgp": "22.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -55.24% vs -38.16% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.60",
          "val2": "-8.20",
          "chgp": "-102.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.30",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-2.30",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.30",
          "val2": "-10.50",
          "chgp": "-55.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.70

-3.60

25.00%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.70

-3.50

22.86%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 22.86% vs -52.17% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-16.60

-8.20

-102.44%

Interest

0.00

0.30

-100.00%

Exceptional Items

0.00

-2.30

100.00%

Consolidate Net Profit

-16.30

-10.50

-55.24%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -55.24% vs -38.16% in Dec 2023

All Annual Results

Company CV

About Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Intensity Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Intensity Therapeutics, Inc.?

Watch in Real-Time

What does Intensity Therapeutics, Inc. do?

Is Intensity Therapeutics, Inc. technically bullish or bearish?

Compare Intensity Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Intensity Therapeutics, Inc.

Company Coordinates